Post on 29-Aug-2020
transcript
Valeant Pharmaceutical
International, Inc.
Jefferies Autumn 2015 Global
Healthcare Conference
November 18, 2015
Laurie W. Little
SVP, Investor Relations
Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to, statements regarding projected, estimated and forecasted revenue and sales, anticipated patent exclusivity and projected impact of generic entry following loss of such patent exclusivity, expected business development activities and deal pipeline, expectations respecting target levels of inventory of certain Salix products (including timing of reaching such target levels), anticipated product approvals and product launches (including anticipated timing of and expected impact of such launches and approvals), planned marketing campaigns (including expected investments in such campaigns) and anticipated impact of such campaigns, anticipated uses of free cash flow and expected debt paydown and share buybacks. Forward-looking statements may be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “could,” “should,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant Pharmaceuticals International, Inc. (“Valeant” or the “Company”) undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes, except as required by law.
Non-GAAP Information To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the Company uses non-GAAP financial measures that exclude certain items. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of the Company‟s core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. The Company has provided results with respect to cash earnings per share, adjusted cash flows from operations and organic product growth rates, which are non-GAAP financial measures. The Company has not provided a reconciliation of these non-GAAP financial measures due to the difficulty in forecasting and quantifying the exact amount of the items excluded from the non-GAAP financial measures that will be included in the comparable GAAP financial measures. Reconciliations of historical non-GAAP financials can be found at www.valeant.com.
2
Focused, multinational specialty pharmaceutical company
Headquartered in Laval, Quebec, Canada (NYSE/TSX: VRX)
Unconventional Business Model
Decentralized operating model
Geographical and product diversity
Focus on faster-growing geographies and therapeutic categories
Durable product portfolio with limited patent risk
Significant cash pay component / low exposure to government reimbursement
Financially disciplined M&A
Ownership Culture
Shareholder friendly executive compensation and corporate governance
Commitment to Innovation
Emphasis on bringing new products to the market (output), through internal R&D,
acquisitions and licensing (input)
Focus on late-stage and lower-risk development projects
Who is Valeant?
3
~$1.0B
Strong Growth Platforms(3)
Eye Health (U.S.) Dermatology Rx (U.S.) Consumer (U.S.)
Ex- US(1) Neurology/Dental/Other (2)
~$1.5B ~$0.6B
~$3.9B ~$2.2B ~$0.8B
Valeant LTM rev (1) Includes Japan, Canada, Australia, Western Europe and Emerging Markets
(2) Includes Neuro & Other, Oral Health, Aesthetics, Generics. Growth rate excludes
facial injectable sales from 1H 14
(3) Q2 2015 and Q3 2015, excluding pre acquisition sales
(4) Post Acquisition sales, including part of Q1 2015, full Q2 2015 and Q3 2014 4
Neurology/Dental/Other (2) Salix(4) Salix(3) Dendreon Dendreon(4)
~$0.2B
Based on projected 2015 revenues
1 Includes contact lens, and surgical devices
Asia Latin
America
Central &
Eastern
Europe/
Middle East/
Africa
United
States
Canada /
Australia
By Geography
68%
16%
7% 4%
5%
9%
14%
58%
11%
Devices 1
Gx/BGx
OTC /
Solutions
Rx
7%
Western
Europe
Emerging Markets = ~18%
Highly Diversified Business Portfolio
By Business
5
Public Pay 25% 75
50%
50%
42%
Cash/Private
Pay
23%
Government
Pay
By Gov‟t Reimbursement
77%
By Number of Products
Top 10 Top 20
43%
28%
Highly Diversified Product Revenue Based on projected 2015 revenues
No product greater than 10% of revenue
6
Limited Patent Risk
2015 2016 2017 2018 2019
Products 1) Xenazine
2) Targretin
1) Ziana
2) Zirgan
3) Visudyne
4) Glumetza
5) Zegerid
1) Lotemax
Gel
2) Macugen
1) Acanya
2) Solodyn
3) Istalol
4) Elidel
1) Zyclara
Annual
2014
Sales
~$335 million
~$190 million
~$115 million
~$400 million
~$30 million
7
Ownership Culture
Relentless focus on organic growth
Business units leaders are evaluated on organic growth and cash flows
Each employee has a duty to speak up
Best idea in the room wins
Executive compensation tied to long-term shareholder returns
Front-loaded performance units tied to shareholder returns with
minimum 10% CAGR over 3 years
Shareholder friendly corporate governance
ValueAct (major shareholder since 2007) has representation on the
Board of Directors
Annual executive sessions with top shareholders and Board of Directors
8
Valeant’s Approach to Innovation Innovation critical to the industry and to Valeant
We source innovation through our internal R&D, acquisitions, in-
licensing
We have acquired terrific set of capabilities and technologies over time
Dow (dermatology)
B+L (e.g., Ultra, Victus, Stellaris)
Additional external collaborations (e.g., Cirle navigatino, brodalumab)
We run a lean R&D model focused on productivity – outputs measured
against inputs
Leverage industry overcapacity
Outsource commodity services
Focus on critical skills and capabilities needed to bring new technologies
to market
Spend according to promise of programs - for short and long term
Results of this approach: 20 launches in the U.S. in 2014; rich pipeline
of products for the future sourced from inside, acquisitions and in-
licensing
9
asd
Physician
eBlast/Banners
Medical Education
Speaker Programs
Ad Boards
Physician Campaign
Comprehensive JUBLIA Launch Campaign Extensive professional education and outreach to
Dermatologists and Podiatrists
Extensive print, digital and TV advertising to reach consumers
Over 150 reps supporting launch
Consumer Campaign
Physician Website Physician
Journal Ads
TV DIGITAL Print 10
Launched Early January
Extensive professional education and outreach: product theaters,
webinars, advisory boards, journal and digital advertising
Integrated digital, print and TV consumer campaign beginning Q2
Over 100 sales reps supporting launch
OnextonGel.com
11
Xifaxan TRx‟s up 15% Q3‟15 vs Q2‟15, 25% Q3‟15 vs Q3‟14
Uceris TRx‟s up 20% Q3‟15 vs Q3‟14, Relistor TRx‟s up 36% Q3‟15 vs Q3‟14,
Apriso TRx‟s up 7% Q3‟15 vs Q3‟14, Ruconest TRx‟s up 29% sequentially Q2 to
Q3
Inventories reduced to 8-10 weeks; expect to reach our target of 4-6 weeks by end
of year
Xifaxan Integrated Professional and Consumer Campaign Launched October 5th
Salix Update
TV PRINT DIGITAL
12
Bausch + Lomb ULTRA® Launch Highlights
Revenue: Forecasted to double from
~$45MM in 2015 to $100MM in 2016
Share: #1 Brand in industry that patients
switched to in Q3 2015
Distribution: Gained +13k doorways in
„15 resulting in 22k total ECP‟s with
diagnostic fitting sets
Pipeline: Launching two new products
(multi-focal and toric) to complete the
ULTRA family in „16
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
9.0
Ma
r 1
4
Ap
r 1
4
Ma
y 1
4
Jun
14
Jul 1
4
Au
g 1
4
Se
p 1
4
Oct 1
4
Nov 1
4
De
c 1
4
Jan
15
Fe
b 1
5
Ma
r 1
5
Ap
r 1
5
Ma
y 1
5
Jun
15
Jul 1
5
Au
g 1
5
$ Share FRP Category
2015 DTC Campaign: Delivered over 1B impressions via Digital, Social, and Paid
Search campaign to drive patients to ECP office to request trial
Doctor Engagement: Large scale ECP educational events to >6k ECP‟s
Customer partnerships: Secured several strategic partnerships to strengthen
distribution and new product launch uptake
13
Bausch + Lomb ULTRA® 2016 Launch Activities
Launching Bausch + Lomb ULTRA® for
Presbyopia and Astigmatism in 2016
Expand Bausch + Lomb ULTRA® reach
by 35% of the Market
Halo effect on Spherical business
Investing $25MM in DTC campaign TV, Digital, Social Media, Search
In-office Digital Displays to create 360
campaign
Aggressive Professional Outreach Largest Eye Care Professional Share of Voice
within contact lens industry
High impact launch events to generate
awareness and request of new products
14
Sprout Update
Addyi launched in U.S. on 10/17
145 reps in the field
6 Medical Science Liaisons (MSLs) hired
Launching with prescribing information,
submitting marketing materials to the
Office of Prescription Drug Promotion
(OPDP)
No plans for direct to consumer (DTC)
advertising at this time
15
Valeant Late Stage R&D Portfolio Product Category Description Expected launch year
EnVista Toric Eye Health Toric IOL 2016/2017
Luminesse Eye Health Red Eye Relief 2016/2017
Vesneo Eye Health Glaucoma 2016
Lotemax Gel Next Gen Eye Health Post-operative pain and inflammation 2018
Ultra Plus Powers Eye Health Contact lens 2016
BioTrue Toric Eye Health Contact lens 2016
IDP-118 Dermatology Moderate to severe plaque psoriasis 2017/2018
IDP-120 Dermatology Novel acne combination 2019
IDP-121 Dermatology Acne 2017
IDP-122 Dermatology Psoriasis 2017
Relistor Oral Gastrointestinal Opioid Induced Constipation 2016
Vitesse Eye Health Ultrasonic Vitrectomy 2016
Next Generation Stellaris Eye Health Phaco/ Vitrectomy 2018
Next Generation Thermage Dermatology Skin Tightening 2016
16
Exceeded top line and bottom line Q3 guidance; 5th consecutive quarter of >10%
organic growth
Includes negative FX impact of $172M revenues and $0.13 Cash EPS
Continued outperformance of U.S. businesses, particularly dermatology and
contact lens
Strong organic growth in China (23%), South Korea (15%), and Mexico (10%)
Continued strong Salix performance
IBS-D indication for Xifaxan (including DTC campaign)
Salix inventories reduced to 8-10 weeks
Addyi launched 10/17
Four deals closed in October
Brodalumab
Sprout
Synergetics
Amoun (expected to close today)
Strong cash flow from operations
GAAP cash flow from operations $737M
90% cash conversion
Q3 2015 Highlights
17
Q3 2015 Financial Results
Q3 2015
Q3 2014
Y/Y%
Adjusted
Y/Y% (a)
Total Revenue $2.8 B
(guidance $2.6 – 2.8B) $2.1 B 36% 44%
Cash EPS $2.74
(guidance $2.60 – 2.70) $2.11 30% 36%
GAAP Cash Flow
from Operations $737M $619M 19% 26%
Adjusted Cash Flow
from Operations $865M $771M 12% 18%
a) Negative FX Y/Y Impact: Revenue $172M, Cash EPS $0.13
18
Same Store Sales – Y/Y growth rates for businesses that have
been owned for one year or more
Q3 2015 YTD 2015
Total U.S. 22% 27%
Total Developed 16% 19%
Total Emerging Markets 3% 5%
Total Company 13% 15%
Pro Forma – Y/Y growth rates for entire business, including
businesses that have been acquired within the last year
Q3 2015 YTD 2015
Total U.S. 26% 27%
Total Developed 21% 21%
Total Emerging Markets 4% 5%
Total Company 17% 17%
Q3 2015 Organic Growth
19
Product Q3
2014
Q4
2014
Q1
2015
Q2
2015
Q3
2015
1) Xifaxan - - - 148 220
2) Jublia 13 53 62 102 106
3) Wellbutrin XL* 80 82 68 67 92
4) SofLens* 95 89 81 84 84
5) Xenazine 56 52 57 66 73
6) Provenge - - 30 74 69
7) Solodyn 54 61 57 65 66
8) Ocuvite / Preservision* 62 62 60 59 57
9) ReNu* 59 60 53 59 54
10) Glumetza - - - 26 53
Q3 2015 Top 10 Brands ($M)
Top 30 represent 54% of total company revenue
* Sales depressed on 12 of top 30 products due to FX impact
20
Q3 2014 Q4 2014 Q1 2015 Q2 2015 Q3 2015
Total Revenue $2,056M $2,280M $2,191M $2,732M $2,787
Cost of Goods Sold (% of product sales) 26% 24% 25% 23% 22%
SG&A (% of total revenue) 24% 23% 26% 25% 24%
R&D Expense $59M $59M $56M $81M $102M
Operating Margin (% of total revenue) (excluding amortization) 47% 50% 47% 49% 50%
Cash EPS (Reported) $2.11 $2.58 $2.36 $2.56 $2.74
GAAP Cash Flow from Operations $619M $816M $491M $411M $737M
Adjusted Cash Flow from Operations $771M $624M $708M $773M $865M
Fully Diluted Share Count 341M 342M 343M 351M 351M
Financial Summary
21
Cash Flow (Q1 2014 to Q3 2015)
*Q4 2014 included a one-time $287M gain from the sale of Allergan shares
2014 2015
Q1 Q2 Q3 Q4 Q1 Q2 Q3
GAAP cash flow from
operations
484 376 619 816* 491 411 737
Adjusted cash flow
from operations
636 500 771 624 708 773 865
Adjusted earnings 600 651 719 881 809 897 961
106% 107% Cash conversion 77% 71% 88% 86% 90%
22
Expect to reach ~4-6 weeks target by year end
Increasing full year Salix net sales estimate from
$1.20B to ~$1.35B
Salix Inventory and Drawdown
Actual
Q2
Actual
Q3
Estimated
Q4
Net Sales (including IBS-D) $313M $461M ~$600M
Inventory Reduction $141M $98M ~$100M
Net Sales Adj. for Inventory
Reduction
$454M $559M ~$700M
Beginning Months on Hand 4 - 5 3 - 3.5 2 - 2.5
Ending Months on Hand 3 - 3.5 2 - 2.5 1 - 1.5
23
Liquidity position at end of Q3
$1.5B undrawn revolver
$1.4B of cash
Cash and revolver used to fund transactions closed in
October
Free cash flow will be used for a combination of debt
paydown and general corporate purposes
Committed to debt paydown beyond the mandatory
amortizations required by term loans
We remain committed to getting net leverage to <4.0x
adjusted pro forma EBITDA by the end of 2016
Balance Sheet Update
24
Summary of Valeant’s Business Model
Robust organic growth profile
Geographical and product diversification creates lower-risk profile
Durable product portfolio limits patent expiry exposure
Rich pipeline of low-risk R&D programs
Internal development – e.g. IDP-118, IDP-120, Onexton
Acquisitions – e.g. Vesneo, Brimonidine, Ultra
Product acquisitions/licenses – e.g. Emerade, Croma, brodalumab
Strong cash flows and balance sheet
Absent large transactions, restructuring charges trending to zero
Convergence of GAAP to non-GAAP cash flows
Enhanced capacity to continue acquisition activity as well as
opportunistically paydown debt and/or buy back shares
Disciplined approach to business development
Continue to be disciplined with capital deployment to generate above
average returns for shareholders
25
Valeant Pharmaceutical
International, Inc.
Jefferies Autumn 2015 Global
Healthcare Conference
November 18, 2015
Laurie W. Little
SVP, Investor Relations